ClinicalTrialsFinder
RecruitingPhase 2NCT07660848

A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.

Enrollment

160 participants

Start Date

Aug 14, 2026

Study Type

INTERVENTIONAL

Conditions

Metabolic dysfunction-associated steatohepatitis (MASH)

Summary

The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HRS-4729 Injection, a drug called HRS-4729 Injection Placebo, and others for people with metabolic dysfunction-associated steatohepatitis (mash). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHRS-4729 Injection

HRS-4729 Injection; high dose, low dose

DRUGHRS9531 Injection

HRS9531 Injection; high dose, low dose

DRUGHRS-4729 Injection Placebo

HRS-4729 Injection Placebo

DRUGHRS9531 Injection Placebo

HRS9531 Injection Placebo

Locations(2)

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07660848

Related Trials

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07732400

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

NCT07795164

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444525 locations

Fibrosis Lessens After Metabolic Surgery

NCT0637487522 locations

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

NCT0551947571 locations